search
Back to results

Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis (PICASSO)

Primary Purpose

Intracranial Atherosclerosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Doctormate
Usual Care
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intracranial Atherosclerosis

Eligibility Criteria

30 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Symptomatic cerebral infarction within 30 days of enrollment attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery) that is documented by any of the following: MRA, CTA, or catheter angiography. Percent stenosis will be measured according to WASID criteria (= 1 - [Ds / Dn]) x 100% with Ds [diameter of stenosis] and Dn [diameter of normal vessel]).19
  2. Modified Rankin score of ≤ 3
  3. Age ≥ 30 years and ≤ 90 years. Subjects 30-49 years are required to meet at least one additional criteria (i-vi) provided in the table below to qualify for the study. This additional requirement is to increase the likelihood that the symptomatic intracranial stenosis in subjects 30-49 years is atherosclerotic.

    • i. insulin dependent diabetes for at least 15 years
    • ii. at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event
    • iii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease
    • iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic
    • v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography
    • vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic
  4. Recent (within 30 days) negative pregnancy test in a female who has had any menses in the last 12 months
  5. Subject is willing and able to return in 30 days for close-out visit for the study
  6. Subject is available by phone
  7. Subject is able to apply the conditioning device or has access to another person (family member, friend) who can assist with application of conditioning device if needed
  8. Subject understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent
  9. Subject is able to undergo brain MRI

Exclusion Criteria:

  1. Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform one of these procedures
  2. Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem to an intracranial stenosis
  3. Intracranial tumor (except meningioma) or any intracranial vascular malformation
  4. Thrombolytic therapy within 24 hours prior to enrollment
  5. Progressive neurological signs within 24 hours prior to enrollment
  6. Any intracranial hemorrhage (parenchmal, subarachnoid, subdural, epidural) within 90 days
  7. Any untreated chronic subdural hematoma
  8. Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus
  9. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%
  10. History of upper extremity ischemia, known subclavian or brachial artery stenosis, subclavian steal syndrome, any upper extremity soft tissue, orthopedic or vascular injury, or mastectomy or other procedure that may contraindicate taking blood pressure or having a cuff on the arm for the conditioning treatment
  11. Difference in systolic blood pressure of > 15 mm Hg between both arms
  12. Known allergy to aspirin or clopidogrel
  13. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets < 100,000, hematocrit < 30, INR > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment (AST or ALT > 3 x normal, cirrhosis), subject on dialysis
  14. Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within previous 30 days or planned in the next 30 days after enrollment
  15. Indication for warfarin or heparin beyond enrollment (NOTE: exceptions allowed for subcutaneous heparin for deep vein thrombosis (DVT) prophylaxis while hospitalized)
  16. Diabetic subjects taking sulfonylurea drugs
  17. Severe neurological deficit that renders the subject incapable of living independently
  18. Dementia or psychiatric problem that prevents the subject from following the protocol reliably
  19. Co-morbid conditions that may limit survival to less than 3 months
  20. Pregnancy or of childbearing potential and unwilling to use contraception for the duration of this study
  21. Claustrophobia requiring sedation for MRI
  22. Enrollment in another study that would conflict with the current study

Sites / Locations

  • Medical University of South Carolina

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Ischemic Conditioning

Usual Care

Arm Description

Doctormate device is used daily.

Standard medical care.

Outcomes

Primary Outcome Measures

Percent Change in Cerebral Blood Flow (CBF)
Percent change CBF from baseline to 30 days as determined by ASL MRI imaging.
Change in Putative Blood Biomarkers
Change in the absolute levels of the following biomarkers will be measured from baseline to 30 days: Nitrite, IL-10, SDF1, Micro RNA 144. Lp-PLA2, IL-6. hsCRP, Soluble E selectin, ICAm, MMP-9, PAI-1,tPA, ADMA

Secondary Outcome Measures

Full Information

First Posted
June 30, 2017
Last Updated
September 13, 2019
Sponsor
Medical University of South Carolina
Collaborators
University of Southern California, University of California, Los Angeles, Augusta University
search

1. Study Identification

Unique Protocol Identification Number
NCT03208166
Brief Title
Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Acronym
PICASSO
Official Title
Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
June 15, 2017 (Actual)
Primary Completion Date
May 30, 2018 (Actual)
Study Completion Date
May 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of South Carolina
Collaborators
University of Southern California, University of California, Los Angeles, Augusta University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the effects of the Doctormate device, a specialized blood pressure cuff used to perform remote limb ischemic conditioning, on cerebral blood flow in subjects with intracranial atherosclerosis. Previous studies in patients with narrowing of the brain arteries have shown that this device is safe to use and suggested that if this device is inflated in both arms for 5 minutes, followed by deflation for 5 minutes and repeated 4 times in a row every day for 6-9 months, the risk of another stroke is lowered and the device may increase the blood flow to the brain.
Detailed Description
In this prospective randomized pilot study, 10 eligible high-risk subjects with ICAS will be randomized to RLIC (bilateral upper extremity daily for 30 days) plus medical management (n=5) or medical management alone (n=5). The medical management, which is the standard of care, will be started at study enrollment and continued until close-out in all subjects. It will consist of aspirin 325 mg per day, clopidogrel 75 mg per day, and risk factor management primarily targeting a systolic BP < 140 mmHg and LDL cholesterol < 70 mg /dl. All subjects will undergo baseline brain arterial spin labeling (ASL) and perfusion MRI to measure CBF and have blood drawn for biomarkers 3-5 days after randomization to allow for washout of any effect from the test RLIC treatment that will be done prior to randomization to determine the subjects' tolerability to RLIC treatment. The period of 3-5 days will provide flexibility for scheduling these tests. After the baseline MRI and biomarker tests are completed, the subjects randomized to RLIC will begin daily RLIC for 30 days. Each daily RLIC treatment will consist of 4 cycles of 5-minute inflations of both blood pressure cuffs simultaneously to a pressure of 200 mm Hg with 5 minutes of reperfusion between each inflation using the Doctormate device. All subjects will return for their close-out visits 33-35 days after enrolling in the study and will undergo brain ASL and perfusion MRI and have blood drawn for biomarkers at that visit. The study will be conducted at 4 sites (MUSC, MCG, UCLA, USC) to enable us to evaluate the consistency of CBF measurements across multiple sites and to ensure that the recruitment target of 10 subjects will be met in time to allow for the subsequent NIH grant submission in 2017.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracranial Atherosclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ischemic Conditioning
Arm Type
Experimental
Arm Description
Doctormate device is used daily.
Arm Title
Usual Care
Arm Type
Other
Arm Description
Standard medical care.
Intervention Type
Device
Intervention Name(s)
Doctormate
Intervention Description
Ischemic conditioning device
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Standard medical care
Primary Outcome Measure Information:
Title
Percent Change in Cerebral Blood Flow (CBF)
Description
Percent change CBF from baseline to 30 days as determined by ASL MRI imaging.
Time Frame
Baseline and 30 days
Title
Change in Putative Blood Biomarkers
Description
Change in the absolute levels of the following biomarkers will be measured from baseline to 30 days: Nitrite, IL-10, SDF1, Micro RNA 144. Lp-PLA2, IL-6. hsCRP, Soluble E selectin, ICAm, MMP-9, PAI-1,tPA, ADMA
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Symptomatic cerebral infarction within 30 days of enrollment attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery) that is documented by any of the following: MRA, CTA, or catheter angiography. Percent stenosis will be measured according to WASID criteria (= 1 - [Ds / Dn]) x 100% with Ds [diameter of stenosis] and Dn [diameter of normal vessel]).19 Modified Rankin score of ≤ 3 Age ≥ 30 years and ≤ 90 years. Subjects 30-49 years are required to meet at least one additional criteria (i-vi) provided in the table below to qualify for the study. This additional requirement is to increase the likelihood that the symptomatic intracranial stenosis in subjects 30-49 years is atherosclerotic. i. insulin dependent diabetes for at least 15 years ii. at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event iii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic Recent (within 30 days) negative pregnancy test in a female who has had any menses in the last 12 months Subject is willing and able to return in 30 days for close-out visit for the study Subject is available by phone Subject is able to apply the conditioning device or has access to another person (family member, friend) who can assist with application of conditioning device if needed Subject understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent Subject is able to undergo brain MRI Exclusion Criteria: Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform one of these procedures Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem to an intracranial stenosis Intracranial tumor (except meningioma) or any intracranial vascular malformation Thrombolytic therapy within 24 hours prior to enrollment Progressive neurological signs within 24 hours prior to enrollment Any intracranial hemorrhage (parenchmal, subarachnoid, subdural, epidural) within 90 days Any untreated chronic subdural hematoma Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30% History of upper extremity ischemia, known subclavian or brachial artery stenosis, subclavian steal syndrome, any upper extremity soft tissue, orthopedic or vascular injury, or mastectomy or other procedure that may contraindicate taking blood pressure or having a cuff on the arm for the conditioning treatment Difference in systolic blood pressure of > 15 mm Hg between both arms Known allergy to aspirin or clopidogrel Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets < 100,000, hematocrit < 30, INR > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment (AST or ALT > 3 x normal, cirrhosis), subject on dialysis Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within previous 30 days or planned in the next 30 days after enrollment Indication for warfarin or heparin beyond enrollment (NOTE: exceptions allowed for subcutaneous heparin for deep vein thrombosis (DVT) prophylaxis while hospitalized) Diabetic subjects taking sulfonylurea drugs Severe neurological deficit that renders the subject incapable of living independently Dementia or psychiatric problem that prevents the subject from following the protocol reliably Co-morbid conditions that may limit survival to less than 3 months Pregnancy or of childbearing potential and unwilling to use contraception for the duration of this study Claustrophobia requiring sedation for MRI Enrollment in another study that would conflict with the current study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc I Chimowitz, MD
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29403
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis

We'll reach out to this number within 24 hrs